Naomi Dempsey, MD, discussed developments in the HER2-positive breast cancer space, including personalized approaches, less ...
The investigational new drug application for VNX-101, a gene therapy aimed at treating CD19-positive acute lymphoblastic ...
The phase 3 Shorespan-007 trial will compare bomedemstat with hydroxyurea in patients with treatment-naive essential ...
During a Case-Based Roundtable® event, Hussein A. Tawbi, MD, PhD, and participants look at benefits of nivolumab combinations ...
Alessandra Ferrajoli, MD, discusses the session she was a part of at the 2024 Society of Hematologic Oncology Annual Meeting.
The FDA granted orphan drug designation for elraglusib, a novel drug for treating advanced soft tissue sarcoma.
The digital twin trial arm demonstrated a 52.7% overall response rate at 6 months for prednisone in chronic GVHD, aligning with real-world data.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback